Press release

Interim Report 1 January - 30 September 2008

- A phase ll study with the product candidate TB-402, for the prevention of blood clots, is under preparation to be conducted in several European countries. The first application to start the study, in patients who have received an artificial knee joint, has been submitted.

 - Product candidate BI-505, for treatment of cancer, obtained orphan drug designation in 
     the US for the indication multiple myeloma.

- BioInvent and ThromboGenics entered in June into a strategic license agreement with Roche for development and commercialisation of TB-403. BioInvent and ThromboGenics received in July an upfront payment of EUR 50 million. In addition,BioInvent and ThromboGenics could potentially receive up to EUR 450 million in milestone payments, as well as double digit royalties on potential product sales.

- The first Phase l study with TB-403, for treatment of cancer, was successfully completed in June and showed that TB-403 was safe and well tolerated. The study was conducted in healthy volunteers.

- The follow-up study, the second Phase I trial with TB-403, is a multi-dose study in patients with advanced cancer was started in June.

- The Phase I programme with product candidate BI-204 for treatment of atherosclerosis proceeds as planned. All subjects in the study are expected to be enrolled during the fourth quarter 2008.

- Entered into an agreement in March with Bayer HealthCare for research and development of antibody-based drugs.

- Net revenues for January - September 2008: SEK 229.0 million (140.0).

- Current investments together with cash and bank as of 30 September 2008: SEK 252.7 million (230.3).

- Cash flow from current operations and investment activities for January - September 2008: SEK 35.9 million (22.2).

- Profit after tax for January - September 2008 amounted to SEK 61.6 million (21.9) and the profit after tax per share was SEK 1.11(0.44).

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer and atherosclerosis.

Comments by the CEO
With the turbulence in today's financial markets it is gratifying to report that our projects are making good progress and meeting the objectives set in the individual project plans. Our clinical development portfolio is maturing with several projects advancing to phase II studies. First in line is TB-402, our thrombosis project for which a study including patients undergoing knee surgery is expected to begin toward the end of the year. The study is planned to be carried out in several European countries.